{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:44:47Z","timestamp":1794638687881,"version":"4.9.1"},"reference-count":74,"publisher":"Elsevier","isbn-type":[{"value":"9780128211083","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.pbr.2020.06.019","type":"book-chapter","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T17:31:50Z","timestamp":1595439110000},"page":"143-170","source":"Crossref","is-referenced-by-count":67,"title":["Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine\u2014The monoclonal antibodies and gepants"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pbr.2020.06.019_bb0015","series-title":"Ubrelvy [Package Insert]","author":"Allergan USA, Inc","year":"2019"},{"key":"10.1016\/bs.pbr.2020.06.019_bb9000","unstructured":"Amgen USA, Inc, 2020. Aimovig [Package Insert]."},{"issue":"10","key":"10.1016\/bs.pbr.2020.06.019_bb0020","doi-asserted-by":"crossref","first-page":"104286","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.002","article-title":"Ischemic stroke associated with calcitonin gene-related peptide inhibitor therapy for migraine: a case report","volume":"28","author":"Aradi","year":"2019","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"12","key":"10.1016\/bs.pbr.2020.06.019_bb0025","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.0000000000004391","article-title":"Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study","volume":"89","author":"Ashina","year":"2017","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/bs.pbr.2020.06.019_bb0030","doi-asserted-by":"crossref","DOI":"10.1177\/0333102419888222","article-title":"Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions","volume":"39","author":"Ashina","year":"2019","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/bs.pbr.2020.06.019_bb0035","doi-asserted-by":"crossref","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0040","series-title":"Nurtec [Package Insert]","author":"Biohaven Pharmaceuticals Inc","year":"2020"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0045","series-title":"Vyepti [Package Insert]","author":"BioPharmaceuticals LS, Inc","year":"2020"},{"issue":"1","key":"10.1016\/bs.pbr.2020.06.019_bb0050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12883-018-1193-2","article-title":"A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","volume":"18","author":"Camporeale","year":"2018","journal-title":"BMC Neurol."},{"issue":"14","key":"10.1016\/bs.pbr.2020.06.019_bb0055","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","volume":"81","author":"Cernuda-Morollon","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.pbr.2020.06.019_bb0060","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine","volume":"156","author":"Cernuda-Moroll\u00f3n","year":"2015","journal-title":"Pain"},{"issue":"4","key":"10.1016\/bs.pbr.2020.06.019_bb0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0333102415593088","article-title":"Treatment of medication-overuse headache: a systematic review","volume":"36","author":"Chiang","year":"2015","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/bs.pbr.2020.06.019_bb0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1526-4610.2010.01799.x","article-title":"Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial","volume":"51","author":"Connor","year":"2010","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0080","doi-asserted-by":"crossref","first-page":"107528","DOI":"10.1016\/j.pharmthera.2020.107528","article-title":"Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans","volume":"211","author":"De Vries","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/bs.pbr.2020.06.019_bb0085","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/head.13316","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina","volume":"58","author":"Depre","year":"2018","journal-title":"Headache"},{"issue":"24","key":"10.1016\/bs.pbr.2020.06.019_bb0090","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.pbr.2020.06.019_bb0095","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0333102410388435","article-title":"BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study","volume":"31","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/bs.pbr.2020.06.019_bb0100","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/bs.pbr.2020.06.019_bb0105","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"issue":"19","key":"10.1016\/bs.pbr.2020.06.019_bb0110","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/bs.pbr.2020.06.019_bb0115","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.pbr.2020.06.019_bb0120","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/head.13766","article-title":"Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0125","series-title":"Emgality [Package Insert]","author":"Eli Lilly and Company","year":"2019"},{"issue":"1","key":"10.1016\/bs.pbr.2020.06.019_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","article-title":"CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?","volume":"20","author":"Favoni","year":"2019","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","article-title":"Pharmacokinetics interactions of monoclonal antibodies","volume":"111","author":"Ferri","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/bs.pbr.2020.06.019_bb0140","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"17","author":"Stovner","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/bs.pbr.2020.06.019_bb0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann. Neurol."},{"issue":"22","key":"10.1016\/bs.pbr.2020.06.019_bb0150","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl J. Med."},{"issue":"15 Supplement","key":"10.1016\/bs.pbr.2020.06.019_bb0155","article-title":"Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b\/3 study","volume":"92","author":"Goadsby","year":"2019","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/bs.pbr.2020.06.019_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/0333102419869918","article-title":"Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/bs.pbr.2020.06.019_bb0165","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40263-015-0253-z","article-title":"Targeting CGRP: A new era for migraine treatment","volume":"29","author":"Goldberg","year":"2015","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/bs.pbr.2020.06.019_bb0170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/bs.pbr.2020.06.019_bb0175","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0333102410368444","article-title":"Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura","volume":"30","author":"Hansen","year":"2010","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/bs.pbr.2020.06.019_bb0180","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1526-4610.2011.01861.x","article-title":"Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine","volume":"51","author":"Hansen","year":"2011","journal-title":"Headache"},{"issue":"6","key":"10.1016\/bs.pbr.2020.06.019_bb0185","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0333102411398399","article-title":"Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine","volume":"31","author":"Hewitt","year":"2011","journal-title":"Cephalalgia"},{"issue":"9656","key":"10.1016\/bs.pbr.2020.06.019_bb0190","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","article-title":"Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial","volume":"372","author":"Ho","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/bs.pbr.2020.06.019_bb0195","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.pbr.2020.06.019_bb0200","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.npep.2013.10.010","article-title":"CGRP and migraine: could PACAP play a role too?","volume":"47","author":"Kaiser","year":"2013","journal-title":"Neuropeptides"},{"issue":"10","key":"10.1016\/bs.pbr.2020.06.019_bb0205","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1177\/0333102419840780","article-title":"A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody","volume":"39","author":"Kielbasa","year":"2019","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/bs.pbr.2020.06.019_bb0210","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/head.13439","article-title":"Basic considerations for the use of monoclonal antibodies in migraine","volume":"58","author":"Levin","year":"2018","journal-title":"Headache"},{"issue":"2","key":"10.1016\/bs.pbr.2020.06.019_bb0215","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/bs.pbr.2020.06.019_bb0220","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/bs.pbr.2020.06.019_bb0225","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.pbr.2020.06.019_bb0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/HAB-180347","article-title":"Nomenclature of humanized mAbs: early concepts, current challenges and future perspectives","volume":"27","author":"Mayrhofer","year":"2019","journal-title":"Hum. Antibodies"},{"issue":"3","key":"10.1016\/bs.pbr.2020.06.019_bb0235","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WCO.0000000000000806","article-title":"Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?","volume":"33","author":"Moreno-Ajona","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"11","key":"10.1016\/bs.pbr.2020.06.019_bb0240","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene\u2013related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.pbr.2020.06.019_bb0245","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"issue":"2","key":"10.1016\/bs.pbr.2020.06.019_bb0250","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/pr.54.2.233","article-title":"International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors","volume":"54","author":"Poyner","year":"2002","journal-title":"Pharmacol. Rev."},{"issue":"10161","key":"10.1016\/bs.pbr.2020.06.019_bb0255","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0260","unstructured":"Rimegepant: Drug Information, Lexicomp, UpToDate, Waltham, MA"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0265","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2147\/JPR.S166427","article-title":"Fremanezumab in the treatment of migraines: evidence to date","volume":"12","author":"Robblee","year":"2019","journal-title":"J. Pain Res."},{"issue":"4","key":"10.1016\/bs.pbr.2020.06.019_bb0270","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0333102419884943","article-title":"Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries","volume":"40","author":"Rubio-Beltran","year":"2019","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/bs.pbr.2020.06.019_bb0275","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1468-2982.2000.00146.x","article-title":"Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks","volume":"20","author":"Sarchielli","year":"2000","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/bs.pbr.2020.06.019_bb0280","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tips.2006.06.003","article-title":"Preventive treatment of migraine","volume":"27","author":"Silberstein","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/bs.pbr.2020.06.019_bb0285","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.2012.198","article-title":"Emerging target-based paradigms to prevent and treat migraine","volume":"93","author":"Silberstein","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.pbr.2020.06.019_bb0290","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine","author":"Silberstein","year":"2018"},{"issue":"4","key":"10.1016\/bs.pbr.2020.06.019_bb0295","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.61.4.490","article-title":"Topiramate in migraine prevention: results of a large controlled trial","volume":"61","author":"Silberstein","year":"2004","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2020.06.019_bb0300","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"issue":"1\u20132","key":"10.1016\/bs.pbr.2020.06.019_bb0305","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline","volume":"331","author":"Silberstein","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"22","key":"10.1016\/bs.pbr.2020.06.019_bb0310","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/bs.pbr.2020.06.019_bb0315","doi-asserted-by":"crossref","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1016\/bs.pbr.2020.06.019_bb0320","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/bs.pbr.2020.06.019_bb0325","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/head.13417","article-title":"Anti-calcitonin gene-related peptide (CGRP) therapies: update on a previous review after the American Headache Society 60th scientific meeting, San Francisco, June 2018","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache"},{"issue":"6","key":"10.1016\/bs.pbr.2020.06.019_bb0330","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"issue":"20","key":"10.1016\/bs.pbr.2020.06.019_bb0335","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.pbr.2020.06.019_bb0340","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102420912726","article-title":"Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study","volume":"40","author":"Tepper","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0345","series-title":"Ajovy [Package Insert]","author":"Teva Pharmaceuticals Inc. USA","year":"2018"},{"key":"10.1016\/bs.pbr.2020.06.019_bb0350","unstructured":"Ubrogepant: Drug Information, Lexicomp, UpToDate, Waltham, MA"},{"issue":"1","key":"10.1016\/bs.pbr.2020.06.019_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-0115(86)90071-6","article-title":"Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects","volume":"15","author":"Uddman","year":"1986","journal-title":"Regul Pept."},{"issue":"12","key":"10.1016\/bs.pbr.2020.06.019_bb0360","doi-asserted-by":"crossref","first-page":"e1152","DOI":"10.1212\/01.wnl.0000544321.19316.40","article-title":"Fremanezumab for preventive treatment of migraine: functional status on headache-free days","volume":"91","author":"VanderPluym","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.pbr.2020.06.019_bb0365","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4161\/mabs.29242","article-title":"Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide","volume":"6","author":"Walter","year":"2014","journal-title":"MAbs"},{"issue":"S2","key":"10.1016\/bs.pbr.2020.06.019_bb0370","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/head.13583","article-title":"Targeting CGRP for the prevention of migraine and cluster Headache: a narrative review","volume":"59","author":"Yuan","year":"2019","journal-title":"Headache"},{"issue":"4","key":"10.1016\/bs.pbr.2020.06.019_bb0375","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/HJH.0000000000001649","article-title":"Endogenous calcitonin gene-related peptide suppresses ischemic brain injuries and progression of cognitive decline","volume":"36","author":"Zhai","year":"2018","journal-title":"J. Hypertens."}],"container-title":["Progress in Brain Research","Update on Emerging Treatments for Migraine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612320300947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612320300947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:03:22Z","timestamp":1758751402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612320300947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128211083"],"references-count":74,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2020.06.019","relation":{},"ISSN":["0079-6123"],"issn-type":[{"value":"0079-6123","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}